Business
Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform
GUILFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life science tools company commercializing
About this update from Quantum-si Incorporated
[{"type":"text","content":" GUILFORD, Conn.--(BUSINESS WIRE)--\nQuantum-Si Incorporated (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life science tools company commercializing a unique protein sequencing platform, announced today that they have expanded their Platinum early access program to ten sites, with participation from leading academic centers and key industry partners. The early access program introduces the Platinum single molecule sequencing system to key opinion leaders across the globe, for both expansion and development of applications and workflows.\n\n“The Company is experiencing tremendous momentum and demand for participation in our early access program to analyze previously unapproachable levels of biological understanding of the proteome,” said John Stark, Chief Executive Officer of Quantum-Si. “Currently, the scientific and drug development community can only confirm ~20,000 proteoforms or 2% of the estimated 1 million protein structures or variants that may exist in a cell. Sequencing the proteome is poised to expand the overall market similar to how genomics empowered scientists to routinely sequence genes at the nucleic acid level. This is only the beginning for what will be enabled.”\n\nQSI is accelerating the development of applications to address critical unmet needs across key market segments including fundamental biological discovery and research, clinical and therapeutic biomarker development, and broadening single molecule sequencing for multi-omic approaches. With Platinum’s scaled protein analysis of single molecules at amino acid level resolution, early access participants will explore:\n\n\nMulti-omic assay development to expand biological understanding. “Within a month of receiving the instrument, we were able to reproduce and validate protein sequencing data previously generated at Quantum-Si,” said Dr. Andrew Griffiths, Professor at the Ecole Superieure de Physique et de Chimie Industrielles (ESPCI) in Paris. “We are now using the instrument to run our own samples to develop single molecule screening for directed evolution, parallelized single molecule counting applications and single-cell multi-omics.”\n\n“Advancements in life science technologies are required to enable a greater understanding of molecular changes that cause disease, enabling greater resolution of cell and fundamental protein structure,” sa...